A practical synthesis of the platelet fibrinogen antagonist, elarofiban
JH Cohen, ME Bos, S Cesco-Cancian…
Index: Cohen, Judith H.; Roessler, Armin; Scott, Lorraine; Sorgi, Kirk L.; Villani Jr., Frank J.; Webster, Robin R. H.; Weh, Christian; Bos, Mary Ellen; Cesco-Cancian, Sergio; Harris, Bruce D.; Hortenstine, John T.; Justus, Michael; Maryanoff, Cynthia A.; Mills, John; Muller, Stefan Organic Process Research and Development, 2003 , vol. 7, # 6 p. 866 - 872
Full Text: HTML
Citation Number: 14
Abstract
Elarofiban is a novel, nonpeptide, orally active fibrinogen receptor antagonist useful for the treatment of platelet mediated thrombotic disorders (Costanzo, MJ; Hoekstra, WJ; Maryanoff, BE WO, 97/41102, 1997). Herein we describe the process research that was carried out for the synthesis of elarofiban that eventually led to the development of a safe and cost-effective commercial scale process.
Related Articles:
[Froelund, Bente; Kristiansen, Uffe; Brehm, Lotte; Hansen, Annette B.; Krogsgaard-Larsen, Povl; Falch, Erik Journal of Medicinal Chemistry, 1995 , vol. 38, # 17 p. 3287 - 3296]
[Froelund, Bente; Kristiansen, Uffe; Brehm, Lotte; Hansen, Annette B.; Krogsgaard-Larsen, Povl; Falch, Erik Journal of Medicinal Chemistry, 1995 , vol. 38, # 17 p. 3287 - 3296]